189 related articles for article (PubMed ID: 34521116)
1. Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium.
DeFilipp Z; Alousi AM; Pidala JA; Carpenter PA; Onstad LE; Arai S; Arora M; Cutler CS; Flowers MED; Kitko CL; Chen GL; Lee SJ; Hamilton BK
Blood Adv; 2021 Oct; 5(20):4278-4284. PubMed ID: 34521116
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of Cutaneous Disease Severity Estimates on Survival Outcomes in Patients With Chronic Graft-vs-Host Disease.
Baumrin E; Baker LX; Byrne M; Martin PJ; Flowers ME; Onstad L; El Jurdi N; Chen H; Beeghly-Fadiel A; Lee SJ; Tkaczyk ER
JAMA Dermatol; 2023 Apr; 159(4):393-402. PubMed ID: 36884224
[TBL] [Abstract][Full Text] [Related]
3. Chronic Graft-versus-Host Disease, Nonrelapse Mortality, and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis.
Bhatt VR; Wang T; Chen K; Kitko CL; MacMillan ML; Pidala JA; Al Malki MM; Badawy SM; Beitinjaneh A; Ganguly S; Hamilton B; Hildebrandt GC; Lekakis LJ; Liu H; Maziarz RT; Modi D; Murthy HS; Preussler JM; Sharma A; Spellman SR; Arora M; Lee SJ
Transplant Cell Ther; 2022 Jan; 28(1):34-42. PubMed ID: 34637965
[TBL] [Abstract][Full Text] [Related]
4. National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen.
Saillard C; Crocchiolo R; Furst S; El-Cheikh J; Castagna L; Signori A; Oudin C; Faucher C; Lemarie C; Chabannon C; Granata A; Blaise D
Leuk Lymphoma; 2014 May; 55(5):1106-12. PubMed ID: 23822538
[TBL] [Abstract][Full Text] [Related]
5. Incidence and Outcome of Atypical Manifestations of Chronic Graft-versus-Host Disease: Results From a Retrospective Single-Center Analysis.
Doering J; Perl M; Weber D; Banas B; Schulz C; Hamer OW; Angstwurm K; Holler E; Herr W; Edinger M; Wolff D; Fante MA
Transplant Cell Ther; 2023 Dec; 29(12):772.e1-772.e10. PubMed ID: 37777112
[TBL] [Abstract][Full Text] [Related]
6. Incidence, Risk Factors, and Outcomes of Chronic Graft-versus-Host Disease in Pediatric Patients with Hematologic Malignancies after T Cell-Replete Myeloablative Haploidentical Hematopoietic Stem Cell Transplantation with Antithymocyte Globulin/Granulocyte Colony-Stimulating Factor.
Tang FF; Cheng YF; Xu LP; Zhang XH; Yan CH; Han W; Chen YH; Huang XJ; Wang Y
Biol Blood Marrow Transplant; 2020 Sep; 26(9):1655-1662. PubMed ID: 32504861
[TBL] [Abstract][Full Text] [Related]
7. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.
Sabry W; Le Blanc R; Labbé AC; Sauvageau G; Couban S; Kiss T; Busque L; Cohen S; Lachance S; Roy DC; Roy J
Biol Blood Marrow Transplant; 2009 Aug; 15(8):919-29. PubMed ID: 19589481
[TBL] [Abstract][Full Text] [Related]
8. The National Institutes of Health criteria for classification and scoring of chronic graft versus host disease: long-term follow-up of a single center series.
Tecchio C; Mosna F; Andreini A; Paoli L; Di Bella R; de Sabata D; Sorio M; Pizzolo G; Benedetti F
Leuk Lymphoma; 2013 May; 54(5):1020-7. PubMed ID: 23035648
[TBL] [Abstract][Full Text] [Related]
9. Frailty in Patients with Chronic Graft-versus-Host Disease.
Rashid N; Arora M; Jurdi NE; Onstad L; Pidala JA; Flowers ME; Lee SJ
Transplant Cell Ther; 2023 Jun; 29(6):367-374. PubMed ID: 36921916
[TBL] [Abstract][Full Text] [Related]
10. Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival.
Moon JH; Sohn SK; Lambie A; Ellis L; Hamad N; Uhm J; Gupta V; Lipton JH; Messner HA; Kuruvilla J; Kim D
Biol Blood Marrow Transplant; 2014 Apr; 20(4):556-63. PubMed ID: 24447907
[TBL] [Abstract][Full Text] [Related]
11. The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation.
Thepot S; Zhou J; Perrot A; Robin M; Xhaard A; de Latour RP; Ades L; Ribaud P; Petropoulou AD; Porcher R; Socié G
Leukemia; 2010 Nov; 24(11):1852-8. PubMed ID: 20827288
[TBL] [Abstract][Full Text] [Related]
12. Ocular Chronic Graft-versus-Host Disease and Its Relation to Other Organ Manifestations and Outcomes after Allogeneic Hematopoietic Cell Transplantation.
Jeppesen H; Gjærde LK; Lindegaard J; Julian HO; Heegaard S; Sengeløv H
Transplant Cell Ther; 2022 Dec; 28(12):833.e1-833.e7. PubMed ID: 36002105
[TBL] [Abstract][Full Text] [Related]
13. Higher Total Body Irradiation Dose Intensity in Fludarabine/TBI-Based Reduced-Intensity Conditioning Regimen Is Associated with Inferior Survival in Non-Hodgkin Lymphoma Patients Undergoing Allogeneic Transplantation.
Hamadani M; Khanal M; Ahn KW; Litovich C; Chow VA; Eghtedar A; Karmali R; Winter A; Fenske TS; Sauter C; Kharfan-Dabaja MA; Awan FT
Biol Blood Marrow Transplant; 2020 Jun; 26(6):1099-1105. PubMed ID: 32165327
[TBL] [Abstract][Full Text] [Related]
14. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation.
Baron F; Labopin M; Niederwieser D; Vigouroux S; Cornelissen JJ; Malm C; Vindelov LL; Blaise D; Janssen JJ; Petersen E; Socié G; Nagler A; Rocha V; Mohty M
Leukemia; 2012 Dec; 26(12):2462-8. PubMed ID: 22699419
[TBL] [Abstract][Full Text] [Related]
15. Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant.
Aziz MD; Shah J; Kapoor U; Dimopoulos C; Anand S; Augustine A; Ayuk F; Chaudhry M; Chen YB; Choe HK; Etra A; Gergoudis S; Hartwell MJ; Hexner EO; Hogan WJ; Kitko CL; Kowalyk S; Kröger N; Merli P; Morales G; Nakamura R; Ordemann R; Pulsipher MA; Qayed M; Reshef R; Rösler W; Schechter T; Schreiner E; Srinagesh H; Wölfl M; Wudhikarn K; Yanik G; Young R; Özbek U; Ferrara JLM; Levine JE
Leukemia; 2020 Jul; 34(7):1898-1906. PubMed ID: 32020045
[TBL] [Abstract][Full Text] [Related]
16. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Morbidity and Mortality in Children with Chronic Graft-versus-Host Disease Classified by National Institutes of Health Consensus Criteria after Allogeneic Hematopoietic Stem Cell Transplantation.
Inagaki J; Moritake H; Nishikawa T; Hyakuna N; Okada M; Suenobu S; Nagai K; Honda Y; Shimomura M; Fukano R; Noguchi M; Kurauchi K; Tanioka S; Okamura J
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1973-80. PubMed ID: 26234723
[TBL] [Abstract][Full Text] [Related]
18. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
19. Effects of Acute and Chronic Graft-versus-myelodysplastic Syndrome on Long-term Outcomes Following Allogeneic Hematopoietic Cell Transplantation.
Konuma T; Ishiyama K; Igarashi A; Uchida N; Ozawa Y; Fukuda T; Ueda Y; Matsuoka KI; Mori T; Katayama Y; Onizuka M; Ichinohe T; Atsuta Y;
Clin Cancer Res; 2020 Dec; 26(24):6483-6493. PubMed ID: 32895232
[TBL] [Abstract][Full Text] [Related]
20. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
